atomoxetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives 256 83015-26-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • LY139603
  • strattera
  • atomoxetine
  • tomoxetine
  • (-)-Tomoxetine
  • atomoxetine hydrochloride
  • tomoxetine hydrochloride
  • atomoxetine HCl
  • tomoxetine HCl
A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
  • Molecular weight: 255.36
  • Formula: C17H21NO
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 21.26
  • ALOGS: -4.82
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 27.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.39 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 94 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 26, 2002 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 216.35 19.25 130 8536 60381 53280019
Prescribed overdose 159.45 19.25 66 8600 13793 53326607
Tic 112.25 19.25 29 8637 1353 53339047
Aggression 106.76 19.25 59 8607 23344 53317056
Irritability 106.60 19.25 65 8601 30888 53309512
Abnormal behaviour 99.40 19.25 55 8611 21811 53318589
Agitation 79.37 19.25 70 8596 58556 53281844
Tachycardia 76.51 19.25 91 8575 108121 53232279
Crying 74.71 19.25 46 8620 22216 53318184
Depression 70.71 19.25 115 8551 182937 53157463
Myocarditis 70.13 19.25 32 8634 8436 53331964
Intentional self-injury 66.93 19.25 45 8621 25239 53315161
Suicide attempt 66.14 19.25 63 8603 58105 53282295
Attention deficit hyperactivity disorder 61.55 19.25 21 8645 2571 53337829
Overdose 59.31 19.25 80 8586 107656 53232744
Disturbance in attention 58.80 19.25 47 8619 34336 53306064
Intentional overdose 48.25 19.25 57 8609 67148 53273252
Somnolence 47.44 19.25 92 8574 167642 53172758
Seizure 45.44 19.25 78 8588 129431 53210969
Blepharospasm 45.41 19.25 17 8649 2719 53337681
Anxiety 45.17 19.25 99 8567 196605 53143795
Raynaud's phenomenon 45.13 19.25 14 8652 1268 53339132
Psychomotor hyperactivity 42.07 19.25 24 8642 10072 53330328
Mania 41.10 19.25 25 8641 11804 53328596
Liver injury 39.46 19.25 31 8635 22072 53318328
Loss of consciousness 39.02 19.25 68 8598 114144 53226256
Trichotillomania 38.99 19.25 8 8658 131 53340269
Mood swings 38.95 19.25 28 8638 17458 53322942
Impulsive behaviour 38.75 19.25 13 8653 1511 53338889
Anger 37.53 19.25 24 8642 12366 53328034
Electrocardiogram QT prolonged 37.47 19.25 46 8620 56357 53284043
Supine hypertension 36.87 19.25 7 8659 75 53340325
Dystonia 36.44 19.25 24 8642 12997 53327403
Oppositional defiant disorder 34.14 19.25 6 8660 40 53340360
Aspartate aminotransferase increased 34.01 19.25 54 8612 83975 53256425
Bipolar I disorder 33.29 19.25 12 8654 1725 53338675
Mydriasis 31.99 19.25 21 8645 11305 53329095
Educational problem 31.30 19.25 8 8658 357 53340043
Obsessive-compulsive disorder 31.02 19.25 14 8652 3596 53336804
Heart rate increased 30.73 19.25 51 8615 82264 53258136
Renal tubular acidosis 29.50 19.25 11 8655 1740 53338660
Thinking abnormal 28.51 19.25 19 8647 10489 53329911
Rheumatoid arthritis 28.37 19.25 8 8658 314523 53025877
Drug screen positive 27.01 19.25 13 8653 3859 53336541
Piloerection 26.91 19.25 7 8659 335 53340065
Feeling abnormal 26.49 19.25 64 8602 135237 53205163
Congestive hepatopathy 25.06 19.25 11 8655 2645 53337755
Alanine aminotransferase increased 24.25 19.25 50 8616 95045 53245355
Dysmenorrhoea 24.23 19.25 12 8654 3789 53336611
Hypomania 24.16 19.25 13 8653 4869 53335531
Social avoidant behaviour 23.75 19.25 11 8655 2997 53337403
Mood altered 23.74 19.25 19 8647 13882 53326518
Psychotic disorder 23.22 19.25 24 8642 24361 53316039
Diarrhoea 22.71 19.25 42 8624 625504 52714896
Emotional disorder 22.66 19.25 18 8648 13012 53327388
Pneumonia 22.34 19.25 20 8646 407149 52933251
Personality change 21.51 19.25 13 8653 6064 53334336
Insomnia 21.47 19.25 73 8593 186999 53153401
Hepatitis 21.46 19.25 27 8639 33867 53306533
Abnormal dreams 21.40 19.25 16 8650 10585 53329815
Migraine 21.35 19.25 43 8623 80374 53260026
Acute kidney injury 20.18 19.25 8 8658 253860 53086540
Lymphocytic hypophysitis 20.02 19.25 5 8661 203 53340197
Merycism 20.02 19.25 5 8661 203 53340197
Generalised tonic-clonic seizure 19.97 19.25 24 8642 28734 53311666
Palpitations 19.58 19.25 48 8618 102300 53238100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 671.28 22.62 332 14358 37751 32461085
Tic 581.28 22.62 144 14546 1950 32496886
Aggression 550.96 22.62 294 14396 39095 32459741
Prescribed overdose 482.57 22.62 176 14514 9343 32489493
Abnormal behaviour 348.52 22.62 190 14500 26276 32472560
Anger 258.44 22.62 120 14570 11784 32487052
Irritability 241.44 22.62 146 14544 24508 32474328
Crying 208.78 22.62 84 14606 5812 32493024
Intentional self-injury 191.72 22.62 103 14587 13797 32485039
Psychomotor hyperactivity 174.30 22.62 84 14606 8955 32489881
Testicular pain 170.15 22.62 60 14630 2876 32495960
Oppositional defiant disorder 159.99 22.62 39 14651 490 32498346
Ejaculation disorder 143.42 22.62 41 14649 982 32497854
Homicidal ideation 133.61 22.62 49 14641 2631 32496205
Agitation 133.07 22.62 146 14544 57090 32441746
Suicide attempt 126.33 22.62 118 14572 38126 32460710
Mood swings 125.30 22.62 65 14625 8100 32490736
Urinary hesitation 121.16 22.62 44 14646 2297 32496539
Disturbance in attention 118.79 22.62 93 14597 23660 32475176
Impulsive behaviour 112.75 22.62 41 14649 2148 32496688
Anxiety 108.89 22.62 172 14518 95833 32403003
Heart rate increased 108.28 22.62 113 14577 41715 32457121
Depressed mood 105.49 22.62 78 14612 18222 32480614
Attention deficit hyperactivity disorder 104.95 22.62 39 14651 2173 32496663
Acute kidney injury 102.66 22.62 8 14682 293460 32205376
Death 98.32 22.62 26 14664 382491 32116345
Pneumonia 97.47 22.62 21 14669 355231 32143605
Mood altered 95.58 22.62 56 14634 8848 32489988
Decreased eye contact 92.96 22.62 25 14665 474 32498362
Bruxism 92.53 22.62 33 14657 1634 32497202
Hallucination, auditory 90.30 22.62 57 14633 10293 32488543
Depression 90.11 22.62 159 14531 96901 32401935
Somnolence 89.94 22.62 165 14525 103632 32395204
Insomnia 86.29 22.62 159 14531 100189 32398647
Drug screen positive 80.48 22.62 39 14651 4202 32494634
Mania 76.49 22.62 50 14640 9582 32489254
Palpitations 75.39 22.62 87 14603 35882 32462954
Product substitution issue 72.85 22.62 50 14640 10386 32488450
Psychotic disorder 72.08 22.62 69 14621 22951 32475885
Self-injurious ideation 70.94 22.62 27 14663 1607 32497229
Alanine aminotransferase increased 70.78 22.62 127 14563 78352 32420484
Mydriasis 70.39 22.62 41 14649 6405 32492431
Dystonia 69.71 22.62 49 14641 10574 32488262
Educational problem 66.21 22.62 19 14671 461 32498375
Feeling abnormal 65.31 22.62 106 14584 60317 32438519
Tachycardia 65.04 22.62 123 14567 78965 32419871
Aspartate aminotransferase increased 64.41 22.62 111 14579 66318 32432518
Seizure 61.36 22.62 141 14549 103713 32395123
Anaemia 59.63 22.62 14 14676 223610 32275226
Sepsis 59.40 22.62 3 14687 158831 32340005
Electrocardiogram QT prolonged 59.28 22.62 81 14609 39560 32459276
Suicidal behaviour 59.20 22.62 23 14667 1448 32497388
Dysuria 58.38 22.62 64 14626 24946 32473890
Dyskinesia 56.13 22.62 61 14629 23542 32475294
Diarrhoea 55.63 22.62 50 14640 364752 32134084
Choreoathetosis 55.30 22.62 20 14670 1031 32497805
Penile discharge 54.05 22.62 11 14679 55 32498781
Blood alkaline phosphatase increased 53.17 22.62 69 14621 32063 32466773
Retching 52.12 22.62 34 14656 6491 32492345
Nervousness 52.09 22.62 44 14646 12435 32486401
Emotional disorder 50.06 22.62 31 14659 5410 32493426
Trismus 49.65 22.62 24 14666 2571 32496265
Affect lability 46.86 22.62 26 14664 3702 32495134
Generalised tonic-clonic seizure 43.35 22.62 50 14640 20589 32478247
Febrile neutropenia 42.44 22.62 3 14687 119563 32379273
Headache 42.32 22.62 188 14502 196009 32302827
Gilbert's syndrome 40.76 22.62 8 14682 32 32498804
General physical health deterioration 40.60 22.62 3 14687 115256 32383580
Screaming 39.43 22.62 17 14673 1397 32497439
Social avoidant behaviour 39.36 22.62 22 14668 3177 32495659
Growth retardation 39.16 22.62 18 14672 1721 32497115
Enuresis 38.87 22.62 19 14671 2085 32496751
Coordination abnormal 37.97 22.62 30 14660 7718 32491118
Paranoia 36.92 22.62 34 14656 10765 32488071
Sexual dysfunction 36.65 22.62 27 14663 6262 32492574
Trichotillomania 36.53 22.62 8 14682 60 32498776
Blood bilirubin increased 36.50 22.62 64 14626 38720 32460116
Tearfulness 36.37 22.62 17 14673 1689 32497147
Thrombocytopenia 36.24 22.62 11 14679 148288 32350548
Panic attack 35.29 22.62 31 14659 9230 32489606
Obsessive-compulsive disorder 35.28 22.62 24 14666 4910 32493926
Hepatic enzyme increased 34.70 22.62 61 14629 36976 32461860
Thinking abnormal 34.67 22.62 25 14665 5610 32493226
Renal failure 34.66 22.62 9 14681 134469 32364367
Sleep disorder 34.56 22.62 51 14639 26701 32472135
Negativism 34.03 22.62 11 14679 402 32498434
Pallor 33.05 22.62 46 14644 22835 32476001
Loss of consciousness 33.02 22.62 97 14593 82610 32416226
Physical assault 32.97 22.62 14 14676 1108 32497728
Apathy 32.91 22.62 26 14664 6689 32492147
Personality change 32.40 22.62 23 14667 5036 32493800
Fight in school 31.17 22.62 5 14685 3 32498833
Cardiac failure 30.59 22.62 3 14687 91670 32407166
Decreased appetite 30.15 22.62 148 14542 160665 32338171
Respiratory failure 29.96 22.62 6 14684 107176 32391660
Abdominal pain upper 29.82 22.62 82 14608 67256 32431580
Tourette's disorder 29.16 22.62 7 14683 82 32498754
Hyperhidrosis 28.91 22.62 84 14606 71084 32427752
Scrotal pain 28.89 22.62 12 14678 899 32497937
Raynaud's phenomenon 28.50 22.62 9 14681 305 32498531
Repetitive speech 28.01 22.62 7 14683 98 32498738
Urinary retention 27.43 22.62 54 14636 35643 32463193
Erectile dysfunction 27.34 22.62 39 14651 19800 32479036
Syncope 27.16 22.62 96 14594 90028 32408808
Pyromania 27.06 22.62 6 14684 48 32498788
Pyrexia 26.25 22.62 67 14623 319901 32178935
Hyperkinesia 26.20 22.62 15 14675 2267 32496569
Hostility 25.84 22.62 11 14679 876 32497960
Asthenia 25.63 22.62 42 14648 235902 32262934
Abdominal discomfort 25.22 22.62 66 14624 52558 32446278
Sedation 24.91 22.62 36 14654 18490 32480346
Amphetamines positive 24.62 22.62 7 14683 164 32498672
Speech disorder 24.28 22.62 43 14647 26210 32472626
Vomiting 23.93 22.62 185 14505 235372 32263464
Dyspnoea 23.81 22.62 84 14606 361961 32136875
Chest pain 23.78 22.62 115 14575 124022 32374814
Oedema peripheral 23.61 22.62 11 14679 114080 32384756
Hyponatraemia 23.44 22.62 3 14687 74510 32424326
Dysphoria 23.39 22.62 14 14676 2297 32496539
Semen analysis abnormal 23.26 22.62 5 14685 34 32498802
Myocardial infarction 23.24 22.62 14 14676 125662 32373174
Poor quality sleep 23.01 22.62 23 14667 8051 32490785
Appendicitis 22.83 22.62 24 14666 8913 32489923
Pain 22.67 22.62 31 14659 187525 32311311

Pharmacologic Action:

SourceCodeDescription
ATC N06BA09 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
FDA EPC N0000175695 Norepinephrine Reuptake Inhibitor
CHEBI has role CHEBI:35469 thymoanaleptics
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Delay when starting to pass urine contraindication 5972002
Priapism contraindication 6273006 DOID:9286
Suicidal thoughts contraindication 6471006
Sinus tachycardia contraindication 11092001
Bipolar disorder contraindication 13746004 DOID:3312
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Feeling agitated contraindication 24199005
Orthostatic hypotension contraindication 28651003
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Feeling irritable contraindication 55929007
Aggressive behavior contraindication 61372001
Cerebrovascular disease contraindication 62914000 DOID:6713
Psychotic disorder contraindication 69322001
Cardiomyopathy contraindication 85898001 DOID:0050700
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 8.69 CHEMBL CHEMBL
Sodium-dependent serotonin transporter Transporter Kd 8.05 CHEMBL
Sodium-dependent dopamine transporter Transporter Kd 5.97 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 4.77 WOMBAT-PK
G protein-activated inward rectifier potassium channel 2 Ion channel IC50 4.28 WOMBAT-PK
Kir3.1/Kir3.2 Ion channel IC50 4.48 WOMBAT-PK
Kir3.1/Kir3.4 Ion channel IC50 4.85 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.68 CHEMBL
Krueppel-like factor 10 Nuclear other IC50 4 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 7.37 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.85 CHEMBL
Transporter Transporter Ki 9.15 CHEMBL
Transporter Transporter Ki 8.40 CHEMBL

External reference:

IDSource
D02574 KEGG_DRUG
82248-59-7 SECONDARY_CAS_RN
353103 RXNORM
C0076823 UMLSCUI
CHEBI:331697 CHEBI
CHEMBL641 ChEMBL_ID
CHEMBL1702 ChEMBL_ID
DB00289 DRUGBANK_ID
D000069445 MESH_DESCRIPTOR_UI
5354 INN_ID
54841 PUBCHEM_CID
7118 IUPHAR_LIGAND_ID
ASW034S0B8 UNII
17042 MMSL
192105 MMSL
45567 MMSL
d04827 MMSL
009862 NDDF
009863 NDDF
407037005 SNOMEDCT_US
407038000 SNOMEDCT_US
412577007 SNOMEDCT_US
4021364 VANDF
4024296 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3227 CAPSULE 10 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3228 CAPSULE 25 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3229 CAPSULE 40 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3238 CAPSULE 18 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3239 CAPSULE 60 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3250 CAPSULE 80 mg ORAL NDA 38 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3251 CAPSULE 100 mg ORAL NDA 38 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3542 CAPSULE 10 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3543 CAPSULE 18 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3544 CAPSULE 25 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3545 CAPSULE 40 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3546 CAPSULE 60 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3547 CAPSULE 80 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3548 CAPSULE 100 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2260 CAPSULE 10 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2261 CAPSULE 18 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2262 CAPSULE 25 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2263 CAPSULE 40 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2264 CAPSULE 60 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2265 CAPSULE 80 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2266 CAPSULE 100 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6908 CAPSULE 40 mg ORAL ANDA 31 sections
STRATTERA HUMAN PRESCRIPTION DRUG LABEL 1 16590-337 CAPSULE 10 mg ORAL NDA 35 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-755 CAPSULE 10 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-756 CAPSULE 18 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-757 CAPSULE 25 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-758 CAPSULE 40 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-759 CAPSULE 60 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-760 CAPSULE 80 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-761 CAPSULE 100 mg ORAL ANDA 33 sections